Imedex® is an industry leader in providing accredited, independent continuing medical education to health care professionals.

April 26 - 27, 2013

New York, New York
The Westin NY Times Square

Continuing Medical Education

ACCMEImedex, LLC® is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Imedex, LLC designates this live meeting for a maximum of 15 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Who Should Attend

This online educational activity is specifically designed for community oncologist, hematologists and other health care professionals involved and/or interested in the therapeutic management of patients with benign or malignant hematologic diseases.

Learning Objectives

Upon successful completion of this activity, participants will be able to:

  • Review the latest data and ongoing clinical trials of novel targeted agents for myeloma, follicular and mantle-cell lymphomas, and acute lymphoblastic leukemia
  • Determine optimal frontline therapy for transplant-eligible and transplant-ineligible myeloma patients
  • Optimize maintenance strategies for myeloma patients after stem-cell transplantation
  • Compare the benefits of R-bendamustine vs. R-CHOP for newly diagnosed follicular lymphoma
  • Weigh the benefits of radioimmunotherapy vs. other strategies for maintenance and salvage therapy in follicular lymphoma
  • Evaluate the potential for maintenance therapy in the second-line setting for Hodgkin's lymphoma
  • Optimize frontline therapy for mantle-cell lymphoma
  • Review the latest findings on best practices for diagnosing and managing benign hematologic disorders
  • Discuss the newest insights into the genetics of acute myeloid leukemia and myelodysplastic syndromes and their potential impact on therapy
  • Assess the potential role of thrombopoietin agonists in treating higher-risk myelodysplastic syndromes
  • Evaluate the potential role for JAK2 inhibitors in treating polycythemia vera and essential thrombocythemia
  • Discuss the utility of FLT3 inhibitors and other novel agents in managing acute leukemias
  • Evaluate the role of novel B-cell receptor signaling inhibitors in managing newly diagnosed and relapsed/refractory chronic lymphocytic leukemia
  • Assess the role of next-generation tyrosine kinase inhibitors vs. imatinib in the frontline and salvage settings for chronic myeloid leukemia